Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2008/091/000247
CTRI/2008/091/000247Not yet recruitingPhase 2

COMPARATIVE EVALUATION OF ACTEOSIDE AND SILYMARIN AS HEPATOPROTECTIVE AGENTS IN ACUTE HEPATITIS PATIENTS-A RANDOMIZED PROSPECTIVE OPEN FRAME STUDY

Government Medical College, Jammu0 sites60 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Enrollment
60
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Acute Hepatitis Patients of different etiologies in the age group of 20-65 years and would be required to abstain from any alternative medication or vitamin supplements during the study.

Exclusion Criteria

  • •1. Patients having any other concomitant disease
  • •2.Patients receiving any other medication affecting hepatic function
  • •3. Patients having received any hepatoprotective agent in the recent past or currently on any hepatoprotective agent 4.Patients with history of smoking, alcohol or any other substance abuse.
  • •5. Pregnancy and lactation.
  • •6. Has participated in any investigational study 4 weeks prior to the enrollment in this study.
  • •7. Known history of hypersensitivity reactions.

Investigators

Similar Trials

Recruiting
Phase 2
Comparison the effects of silymarin and N-acetylcysteine on improvement of, Hepatic and renal Abnormalities in Patients with SeverePreeclampsia in post-partumPreeclampcia.Severe pre-eclampsiaO14.1
IRCT20191231045965N1Shahre-kord University of Medical Sciences60
Not yet recruiting
Phase 4
COMPARING EFFECTIVENESS OF CAPSULE SILYMARIN WITH THAT OF SM FIBRO CAPSULE IN THE MANAGEMENT OF ORAL SUBMUCOUS FIBROSIS
CTRI/2024/01/061326KAKARLA VENKATA SUSMITHA
Not yet recruiting
Phase 4
A study to compare safety and efficacy of silodosin versus mirabegron in patients with lower uretericstone
CTRI/2023/08/057036Dr Rajendera Prasad Government Medical College, Kangra at Tanda, Himachal Pradesh India
Not yet recruiting
Phase 3
Evaluate efficacy and safety of combination of Silodosin and Tadalafil vs. Silodosin or Tadalafil alone in patients with enlarged prostate
CTRI/2020/07/026440I
Not yet recruiting
Phase 2
Silymarin capsule in COVID-19COVID-19 disease.COVID-19U07.1
IRCT20180103038199N10Mashhad University of Medical Sciences140